Personalized 'Living Drug' trial offers hope for kids with tough leukemia

NCT ID NCT03573700

Summary

This study is testing a personalized cell therapy called SJCAR19 for children and young adults (up to age 21) whose acute lymphoblastic leukemia (ALL) has come back or hasn't responded to standard treatments. Doctors collect a patient's own immune cells, modify them in a lab to better target cancer, and then infuse them back into the patient. The main goals are to find the safest and most effective dose, see how long the modified cells last, and check if this treatment can help control the leukemia.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • St. Jude Children's Research Hospital

    Memphis, Tennessee, 38105, United States

Conditions

Explore the condition pages connected to this study.